30 December 2024 - Telix today announces that it has submitted its biologics license application to the US FDA for TLX250-CDx (Zircaix, 89Zr girentuximab) kidney cancer imaging.

TLX250-CDx is an investigational PET drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.

Read Telix Pharmaceuticals press release